182 related articles for article (PubMed ID: 30863015)
1. siRNA-based breast cancer therapy by suppressing 17β-hydroxysteroid dehydrogenase type 1 in an optimized xenograft cell and molecular biology model in vivo.
Li F; Zhu Z; Xue M; He W; Zhang T; Feng L; Lin S
Drug Des Devel Ther; 2019; 13():757-766. PubMed ID: 30863015
[TBL] [Abstract][Full Text] [Related]
2. 17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer.
Day JM; Foster PA; Tutill HJ; Parsons MF; Newman SP; Chander SK; Allan GM; Lawrence HR; Vicker N; Potter BV; Reed MJ; Purohit A
Int J Cancer; 2008 May; 122(9):1931-40. PubMed ID: 18183589
[TBL] [Abstract][Full Text] [Related]
3. A new nonestrogenic steroidal inhibitor of 17β-hydroxysteroid dehydrogenase type I blocks the estrogen-dependent breast cancer tumor growth induced by estrone.
Ayan D; Maltais R; Roy J; Poirier D
Mol Cancer Ther; 2012 Oct; 11(10):2096-104. PubMed ID: 22914440
[TBL] [Abstract][Full Text] [Related]
4. Reductive 17beta-hydroxysteroid dehydrogenases which synthesize estradiol and inactivate dihydrotestosterone constitute major and concerted players in ER+ breast cancer cells.
Zhang CY; Wang WQ; Chen J; Lin SX
J Steroid Biochem Mol Biol; 2015 Jun; 150():24-34. PubMed ID: 25257817
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic profile of PBRM in rodents, a first selective covalent inhibitor of 17β-HSD1 for breast cancer and endometriosis treatments.
Maltais R; Trottier A; Roy J; Ayan D; Bertrand N; Poirier D
J Steroid Biochem Mol Biol; 2018 Apr; 178():167-176. PubMed ID: 29248731
[TBL] [Abstract][Full Text] [Related]
6. The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer.
Purohit A; Tutill HJ; Day JM; Chander SK; Lawrence HR; Allan GM; Fischer DS; Vicker N; Newman SP; Potter BV; Reed MJ
Mol Cell Endocrinol; 2006 Mar; 248(1-2):199-203. PubMed ID: 16414180
[TBL] [Abstract][Full Text] [Related]
7. 17beta-hydroxysteroid dehydrogenase type 1 stimulates breast cancer by dihydrotestosterone inactivation in addition to estradiol production.
Aka JA; Mazumdar M; Chen CQ; Poirier D; Lin SX
Mol Endocrinol; 2010 Apr; 24(4):832-45. PubMed ID: 20172961
[TBL] [Abstract][Full Text] [Related]
8. Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone.
Laplante Y; Cadot C; Fournier MA; Poirier D
Bioorg Med Chem; 2008 Feb; 16(4):1849-60. PubMed ID: 18035543
[TBL] [Abstract][Full Text] [Related]
9. 17beta-hydroxysteroid dehydrogenase type 1 modulates breast cancer protein profile and impacts cell migration.
Aka JA; Zerradi M; Houle F; Huot J; Lin SX
Breast Cancer Res; 2012 Jun; 14(3):R92. PubMed ID: 22691413
[TBL] [Abstract][Full Text] [Related]
10. Development of potential preclinical candidates with promising in vitro ADME profile for the inhibition of type 1 and type 2 17β-Hydroxysteroid dehydrogenases: Design, synthesis, and biological evaluation.
Abdelsamie AS; Salah M; Siebenbürger L; Hamed MM; Börger C; van Koppen CJ; Frotscher M; Hartmann RW
Eur J Med Chem; 2019 Sep; 178():93-107. PubMed ID: 31176098
[TBL] [Abstract][Full Text] [Related]
11. Estradiol-independent modulation of breast cancer transcript profile by 17beta-hydroxysteroid dehydrogenase type 1.
Aka JA; Calvo EL; Lin SX
Mol Cell Endocrinol; 2017 Jan; 439():175-186. PubMed ID: 27544780
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core.
Lilienkampf A; Karkola S; Alho-Richmond S; Koskimies P; Johansson N; Huhtinen K; Vihko K; Wähälä K
J Med Chem; 2009 Nov; 52(21):6660-71. PubMed ID: 19824648
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of 16β-derivatives of 3-(2-bromoethyl)-estra-1,3,5(10)-trien-17β-ol as inhibitors of 17β-HSD1 and/or steroid sulfatase for the treatment of estrogen-dependent diseases.
Lespérance M; Roy J; Djiemeny Ngueta A; Maltais R; Poirier D
Steroids; 2021 Aug; 172():108856. PubMed ID: 33945801
[TBL] [Abstract][Full Text] [Related]
14. Structural basis for species specific inhibition of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1): computational study and biological validation.
Klein T; Henn C; Negri M; Frotscher M
PLoS One; 2011; 6(8):e22990. PubMed ID: 21857977
[TBL] [Abstract][Full Text] [Related]
15. Estrone C15 derivatives--a new class of 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
Messinger J; Husen B; Koskimies P; Hirvelä L; Kallio L; Saarenketo P; Thole H
Mol Cell Endocrinol; 2009 Mar; 301(1-2):216-24. PubMed ID: 19014997
[TBL] [Abstract][Full Text] [Related]
16. Current knowledge of the multifunctional 17β-hydroxysteroid dehydrogenase type 1 (HSD17B1).
He W; Gauri M; Li T; Wang R; Lin SX
Gene; 2016 Aug; 588(1):54-61. PubMed ID: 27102893
[TBL] [Abstract][Full Text] [Related]
17. Discovery of highly potent, nonsteroidal 17β-hydroxysteroid dehydrogenase type 1 inhibitors by virtual high-throughput screening.
Starčević Š; Turk S; Brus B; Cesar J; Lanišnik Rižner T; Gobec S
J Steroid Biochem Mol Biol; 2011 Nov; 127(3-5):255-61. PubMed ID: 21920439
[TBL] [Abstract][Full Text] [Related]
18. Bicyclic substituted hydroxyphenylmethanone type inhibitors of 17 β-hydroxysteroid dehydrogenase Type 1 (17 β-HSD1): the role of the bicyclic moiety.
Oster A; Klein T; Henn C; Werth R; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
ChemMedChem; 2011 Mar; 6(3):476-87. PubMed ID: 21337522
[TBL] [Abstract][Full Text] [Related]
19. Insight into the mode of action and selectivity of PBRM, a covalent steroidal inhibitor of 17β-hydroxysteroid dehydrogenase type 1.
Trottier A; Maltais R; Ayan D; Barbeau X; Roy J; Perreault M; Poulin R; Lagüe P; Poirier D
Biochem Pharmacol; 2017 Nov; 144():149-161. PubMed ID: 28800957
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity study in the class of 6-(3'-hydroxyphenyl)naphthalenes leading to an optimization of a pharmacophore model for 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors.
Marchais-Oberwinkler S; Frotscher M; Ziegler E; Werth R; Kruchten P; Messinger J; Thole H; Hartmann RW
Mol Cell Endocrinol; 2009 Mar; 301(1-2):205-11. PubMed ID: 18950679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
